| scholarly article | Q13442814 |
| P50 | author | Kathryn A. Hanley | Q24809595 |
| Joseph E Blaney | Q112131210 | ||
| Christopher T Hanson | Q115158009 | ||
| Stephen S Whitehead | Q64866574 | ||
| Brian R. Murphy | Q65658906 | ||
| P2093 | author name string | Tammy A Romero | |
| Neeraj S Sathe | |||
| Laura Goddard | |||
| P2860 | cites work | Mfold web server for nucleic acid folding and hybridization prediction | Q24498105 |
| Identification of specific nucleotide sequences within the conserved 3'-SL in the dengue type 2 virus genome required for replication | Q24523550 | ||
| Dengue and dengue hemorrhagic fever | Q24550739 | ||
| Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 | Q24805308 | ||
| Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys | Q27469474 | ||
| Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys | Q27472847 | ||
| Sequence comparison and secondary structure analysis of the 3' noncoding region of flavivirus genomes reveals multiple pseudoknots. | Q27472958 | ||
| A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys | Q27473080 | ||
| Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences | Q27473202 | ||
| Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys | Q27480386 | ||
| Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses | Q27860800 | ||
| Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure | Q27860806 | ||
| Prospects for a dengue virus vaccine | Q29619608 | ||
| The global pandemic of dengue/dengue haemorrhagic fever: current status and prospects for the future | Q30430980 | ||
| Genetically modified, live attenuated dengue virus type 3 vaccine candidates | Q31140519 | ||
| Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers | Q33336929 | ||
| Impact of dengue/dengue hemorrhagic fever on the developing world | Q33784757 | ||
| 5'- and 3'-noncoding regions in flavivirus RNA. | Q35616820 | ||
| Development of a live attenuated dengue virus vaccine using reverse genetics | Q36428460 | ||
| Epidemic Dengue 3 in Central Java, Associated with Low Viremia in Man * | Q36659267 | ||
| Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. | Q39417682 | ||
| Genetic variation in the 3' non-coding region of dengue viruses. | Q39460462 | ||
| Secondary structure of dengue virus type 4 3' untranslated region: impact of deletion and substitution mutations | Q40222010 | ||
| Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication | Q40243124 | ||
| Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. | Q40382643 | ||
| Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication | Q40400756 | ||
| rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. | Q40464785 | ||
| The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. | Q40468552 | ||
| rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers | Q40515729 | ||
| Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity | Q40528042 | ||
| Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | Q40536052 | ||
| Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates | Q40541513 | ||
| Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys | Q40549819 | ||
| A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. | Q40553373 | ||
| Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells | Q40575878 | ||
| A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. | Q40593111 | ||
| Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. | Q40593118 | ||
| Recombination and flavivirus vaccines: a commentary | Q42991651 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| vaccine | Q134808 | ||
| DENV-3 | Q106250534 | ||
| DENV-4 | Q106411493 | ||
| P304 | page(s) | 817-28 | |
| P577 | publication date | 2008-02-06 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4 | |
| P478 | volume | 26 |
| Q59358841 | A Single Mutation at Position 156 in the Envelope Protein of Tembusu Virus Is Responsible for Virus Tissue Tropism and Transmissibility in Ducks |
| Q28741828 | A novel single-dose dengue subunit vaccine induces memory immune responses |
| Q33919503 | A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis |
| Q33988937 | A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial |
| Q35272502 | An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques |
| Q97521587 | Anti-dengue Vaccines: From Development to Clinical Trials |
| Q64883121 | Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. |
| Q33839001 | Bioinformatics in new generation flavivirus vaccines |
| Q35180143 | Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys |
| Q38140035 | Challenges in reducing dengue burden; diagnostics, control measures and vaccines |
| Q38605190 | Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine. |
| Q40239548 | Comparison of full-length genomics sequences between dengue virus serotype 3, parental strain, and its derivatives, and B-cell epitopes prediction from envelope region |
| Q57059015 | Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon |
| Q91711499 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade |
| Q34184711 | Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization |
| Q35206695 | Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine |
| Q24289057 | Ecuador Paraiso Escondido Virus, a New Flavivirus Isolated from New World Sand Flies in Ecuador, Is the First Representative of a Novel Clade in the Genus Flavivirus |
| Q26825663 | Endothelial cells in dengue hemorrhagic fever |
| Q56794148 | Epitope Sequences in Dengue Virus NS1 Protein Identified by Monoclonal Antibodies |
| Q39118535 | Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts |
| Q26864533 | Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus |
| Q34432758 | Flaviviral RNAs: weapons and targets in the war between virus and host |
| Q38289956 | Flavivirus reverse genetic systems, construction techniques and applications: a historical perspective |
| Q26700111 | Functions of the 3' and 5' genome RNA regions of members of the genus Flavivirus |
| Q27486407 | Identification of Mutated Cyclization Sequences That Permit Efficient Replication of West Nile Virus Genomes: Use in Safer Propagation of a Novel Vaccine Candidate |
| Q30395396 | Issues related to recent dengue vaccine development |
| Q28657429 | Molecular archaeology of Flaviviridae untranslated regions: duplicated RNA structures in the replication enhancer of flaviviruses and pestiviruses emerged via convergent evolution |
| Q42630075 | New reverse genetics and transfection methods to rescue arboviruses in mosquito cells |
| Q56795718 | Nucleic Acid-Based Infectious and Pseudo-Infectious Flavivirus Vaccines |
| Q27490989 | Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers |
| Q28595165 | Possible Roles of New Mutations Shared by Asian and American Zika Viruses |
| Q35009119 | Progress towards a dengue vaccine |
| Q34675614 | RNA Structure Duplications and Flavivirus Host Adaptation |
| Q38303232 | Recent progress in dengue vaccine development |
| Q35070580 | Repertoire of virus-derived small RNAs produced by mosquito and mammalian cells in response to dengue virus infection |
| Q42026897 | Replication enhancer elements within the open reading frame of tick-borne encephalitis virus and their evolution within the Flavivirus genus. |
| Q91728039 | Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques |
| Q27487528 | Structural and Functional Studies of the Promoter Element for Dengue Virus RNA Replication |
| Q34070463 | Substitution of NS5 N-terminal domain of dengue virus type 2 RNA with type 4 domain caused impaired replication and emergence of adaptive mutants with enhanced fitness |
| Q36118259 | Targeted mutagenesis as a rational approach to dengue virus vaccine development |
| Q32183359 | The 5' and 3' Untranslated Regions of the Flaviviral Genome |
| Q37324444 | The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers |
| Q37350360 | Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses |
| Q27011587 | Understanding the dengue viruses and progress towards their control |
| Q34238916 | Utility, limitations, and future of non-human primates for dengue research and vaccine development |
| Q37184768 | Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles |
| Q30376550 | Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. |
| Q53165070 | WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. |
| Q57168259 | What Does the Future Hold for Yellow Fever Virus? (II) |
| Q47178548 | Zika Virus Exhibits Lineage-Specific Phenotypes in Cell Culture, in Aedes aegypti Mosquitoes, and in an Embryo Model |
Search more.